Welcome to this November twenty twenty-six run-through of Dermatologic Surgery. We've got four pieces from this issue worth your time — a systematic review on laser treatment of steatocystoma multiplex, a short communication on an unexpected bedside use for near-infrared vein finders, a case report on a new high-magnification dermoscopy technology helping catch a subtle basal cell, and a technique piece on an old plastic surgery trick — the hemostatic net — repurposed for scalp surgery. Let's get into it. First up is a systematic review looking at laser treatments for steatocystoma multiplex. You know the clinical problem here — these are benign sebum-filled dermal cysts, often tied to autosomal dominant KRT17 variants, and they're a real quality-of-life burden when they're disseminated across the trunk or face. The standard surgical answer, excision and drainage, comes with a frustrating combination of high recurrence and poor cosmetic outcome, especially in cosmetically sensitive areas. So the authors set out to ask whether laser therapy — which in theory offers more precise, tissue-sparing ablation — actually delivers better outcomes, and whether there's enough evidence out there to say so. Methodologically, this is a straightforward PRISMA-guided systematic review. They searched MEDLINE, Embase, and CINAHL through November twenty twenty-four, had two independent reviewers screen and extract, and used the Joanna Briggs Institute critical appraisal tools to grade study quality. There's no pooled statistical analysis here — no meta-analytic effect size — and that's worth noting explicitly, because the evidence base itself doesn't support one. What they found were eleven eligible studies out of a hundred sixty-nine screened, and every single one was a case report or small case series, with sample sizes from a single patient up to eight. So rather than crunching numbers, the appropriate methodological move was simply to catalog outcomes by laser modality and grade study quality qualitatively, which is exactly what they did. Quality appraisal came back reassuring on the whole — one high-quality case series, the overwhelming majority of case reports rated high quality, and just one rated moderate due to an unclear history. On results: carbon dioxide laser, at ten thousand six hundred nanometers, was the workhorse, used in six studies covering twelve patients, typically two to three sessions. Recurrence in that CO2 group was around seventeen percent, both recurrences coming from one case series using fully ablative CO2 at relatively low wattage, with recurrence showing up at about four years out. A quarter of CO2 cases had minimal residual scarring, and the rest had none. Other CO2 studies — both fully ablative and fractional — showed complete clearance with no recurrence across follow-up windows from two months out to three years. Erbium-YAG, at two thousand nine hundred forty nanometers, performed beautifully in two single-session cases — complete clearance, no recurrence, no pigmentary change, which makes physical sense given erbium-YAG's shallow, highly water-absorbed ablation profile, ideal for sparing surrounding tissue on the face. Diode lasers, including a single nineteen twenty-seven nanometer device and a combination approach pairing a fourteen fifty nanometer diode with a fifteen fifty nanometer fractionated erbium-doped fiber laser, both achieved high-percentage clearance — one histologically confirmed — with no recurrence at around eight months. The one outlier was a multimodal surgical approach combining resection, mini-incisional capsulectomy, and CO2 puncture evacuation, which hit decent short-term clearance but recurred at sixteen months, with a fifty percent overall recurrence rate in that small group — the authors flag this as supporting evidence that incomplete cyst wall destruction, not just drainage of contents, is the real driver of long-term failure regardless of which energy device you use. The honest limitations here are what you'd expect from a case-report-driven literature: tiny samples, short and inconsistent follow-up, and inconsistent reporting of procedural parameters and concurrent therapies, so you can't really compare across studies with any rigor. The authors' bottom line is that lasers — particularly CO2 and erbium-YAG — look like a heterogeneous but genuinely promising alternative to excision, with favorable scarring profiles, but the evidence is thin enough that this is a hypothesis-generating body of literature, not practice-defining data. For your practice, the practical takeaway is this: laser ablation, especially erbium-YAG or fractional-to-fully-ablative CO2 targeting complete cyst wall destruction rather than mere content expression, is a reasonable option to discuss with patients who have cosmetically sensitive or treatment-refractory steatocystoma multiplex, particularly when they've already been burned by scarring from excision. But don't oversell durability — tell patients recurrence is possible, especially if ablation is incomplete, and recognize this is still an off-label, low-evidence-volume application rather than an established algorithm. Next, a short communication on a clever diagnostic repurposing — using handheld near-infrared vein visualization for point-of-care identification of cutaneous venous malformations. This is not a study, just a case-based observation, so there's no methods section or statistics to walk through — just a clinical pearl. A twenty-nine-year-old man came in with multiple soft subcutaneous nodules with bluish discoloration across his upper arms, chest, and abdomen, present since childhood, previously called lipomas, with the kind of positional size fluctuation and intermittent pain that should already be raising your suspicion for a vascular malformation rather than a lipoma. The authors used an AccuVein AV400, a seven-sixty nanometer near-infrared device marketed for making venipuncture easier, and found it showed dilated, irregular, serpentine venous channels lining up precisely with each palpable nodule. That real-time correlation bumped their suspicion for venous malformation enough to go straight to MRI for confirmation. The teaching point they're making is really about where this sits in the imaging pathway. Duplex ultrasound is usually the first-line study for suspected venous malformations, but for superficial low-flow lesions, it's prone to misinterpretation — signal from an adjacent normal artery can be mistaken for flow within the lesion itself, which is part of why MRI so often ends up being needed anyway to resolve ambiguity. The authors are proposing near-infrared vein visualization as a zero-cost, zero-training, real-time triage step you can do in clinic with a device that already exists in a lot of phlebotomy carts — no gel, no positioning, no specialized operator — to quickly raise or lower your suspicion before you commit to formal imaging. This is genuinely interesting but it's a single case, with no diagnostic accuracy data, no sensitivity or specificity figures, and the authors explicitly call for further study to establish that. So, practical takeaway: this is not practice-changing in the sense of replacing anything in your imaging algorithm, but it's a nice, free adjunct worth trying at the bedside — if you've got one of these vein finders sitting around and you're looking at a bluish, soft, positionally variable nodule that smells like a vascular malformation rather than a lipoma, shining it on there costs you nothing and might sharpen your pretest suspicion before you order MRI. Third, a case report introducing optical super-high magnification dermoscopy — OSHMD — as an aid in recognizing basal cell carcinoma. Again, this is a case report, not a comparative study, so we're walking through a single illustrative patient rather than crunching data. The technology itself is the headline: conventional dermoscopy tops out around ten-power magnification, while this new modality gets up to four hundred-power, revealing vascular morphologies — looped vessels, oak-leaf vessels, arborizing vessels — that are simply invisible at standard magnification but have recently been described as suggestive of basal cell carcinoma. The case was a forty-year-old Fitzpatrick type three man with a slightly brownish papule on the frontal scalp that looked clinically like a pigmented BCC, but standard ten-power dermoscopy was oddly unhelpful — just light brown pigmentation and thin vessels, none of the classic blue-gray ovoid nests or arborizing pattern you'd want to see to clinch the call. Stepping up to four-hundred-power OSHMD, using a Medicam 1000 with a D-Scope III lens, revealed looped vessels and bluish-gray clods, without melanoma-specific features — enough to proceed to excisional biopsy, which confirmed nodular BCC, caught early enough for simple primary closure rather than a flap or graft. The discussion is appropriately measured — looped vessels are actually reported as an uncommon BCC feature, under ten percent of cases, with arborizing vessels and shiny telangiectasias being far more typical. So the real message isn't "looped vessels are the dominant BCC pattern," it's that in lesions where conventional dermoscopy gives you a nondiagnostic, wishy-washy pattern — which happens more often in hypopigmented or clinically subtle presentations — this higher-magnification technology can pull out a secondary, previously undescribed clue that pushes you from uncertain to confident. The authors are upfront that this is still an emerging, essentially experimental modality, and that further studies are needed to validate it and define where it actually fits into routine practice. Practical takeaway for you: not practice-changing yet — this is a single case with a brand-new device most of you don't have access to — but it's worth filing away as a modality to watch, particularly for those frustrating hypopigmented facial or scalp lesions where standard dermoscopy leaves you without a clear read and you're deciding between watchful waiting and biopsy. Last, a technique article on the hemostatic net as an adjunct for bleeding control in scalp surgery. You know the scalp bleeding problem intimately — the galea anchors the skin so tightly that transected vessels can't retract, and you've got five major paired arteries feeding a richly anastomotic subgaleal network, so even a modest excision can turn into a surprisingly bloody field, especially in older patients on anticoagulants. The hemostatic net itself isn't new — it was originally described back in twenty twelve for face-lift and neck-lift procedures to reduce hematoma formation — but this group is describing its application specifically to scalp oncologic surgery. The technique is simple: before excising the tumor, you place a continuous two-oh silk suture, full-thickness through the subcutaneous tissue down to the galea, about a centimeter out from your planned margins. Tightened appropriately, you should see blanching of the surrounding skin with mild cyanosis in the enclosed zone — that's your visual confirmation that you've compressed the subdermal arteriolar, capillary, and venular plexus. You then excise through a drier field, preserve the periosteum, and if you're planning a full-thickness skin graft, that preserved periosteal bed gives you a clean surface for graft adherence. The suture comes out around day five to seven, timed with the graft dressing change. This was applied in eight patients, all with scalp squamous cell carcinoma, mean age eighty-six, with tumors averaging over three centimeters — so a frail, elderly population with large defects, exactly the group where you want to minimize bleeding time and hematoma risk under the graft. All eight healed without delayed graft take, and at one month there were no visible suture marks. The authors also lean on outside data to address the obvious worry — does compressing the subdermal plexus choke off perfusion to the flap or graft bed? Laser-assisted fluorescence angiography studies and a separate retrospective series using this technique with cervicofacial flap reconstruction around the eyelid and cheek showed no significant perfusion compromise and no flap viability issues, which is reassuring since the periosteal vessels you're relying on for graft survival sit below the level of the suture. There are no real limitations beyond the obvious ones inherent to a small technique series — eight patients, single institution, no comparator arm against standard hemostatic methods like electrocautery or staples. And the authors themselves flag an important caveat on applicability: this technique is best suited to planned skin graft reconstruction with periosteum preserved, and they explicitly caution it's less appropriate when you're planning secondary intention healing or a flap closure, since the temporary vascular compression and potential tissue effect could complicate those reconstructive options. Practical takeaway: this one is genuinely actionable. It's cheap, fast, reproducible, and requires no new equipment beyond suture you already have on your tray. If you're doing larger scalp excisions on elderly or anticoagulated patients with a full-thickness graft planned, placing a peripheral hemostatic net before you excise is a low-risk way to dry up your field and potentially shorten operative time — just reserve it for the graft scenario rather than flap or secondary-intention cases. That wraps up this issue — a heterogeneous but promising laser evidence base for steatocystoma multiplex, a neat point-of-care trick with near-infrared vein finders for sorting out vascular malformations from lipomas, an early look at super-high magnification dermoscopy sharpening BCC detection in subtle lesions, and a genuinely practical hemostatic net technique for your next big scalp graft case. Thanks for listening, and we'll see you next month.